SK Bioscience's vaccine center is seen in this undated photo, Andong, North Gyeongsang Province. Courtesy of SK bioscience
SK Bioscience, a biopharmaceutical arm of Korea's SK Group, said Wednesday it will supply 750,000 doses of influenza vaccines to the southern hemisphere market in the first half.
The latest deal marks SK Bioscience's second export of influenza vaccines to the southern hemisphere market, including Southeast Asia and Latin America, following its shipment to Thailand last year, the company said in a press release.
SKYCellflu, launched by SK Bioscience in 2016, is the world's first cell culture-based influenza vaccine, which has obtained the World Health Organization's (WHO) prequalification (PQ) certification, it said.
The company produces the vaccine product at its domestic manufacturing facility L HOUSE in Andong, 188 kilometers south of Seoul.
"Our independently developed vaccines have already proven their competitiveness in the global market by acquiring WHO PQ certification. With these vaccines, we will continue expanding our global presence," SK Bioscience Chief Executive Officer Ahn Jae-yong said in the release. (Yonhap)
English (United States) ·